Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
about
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerFifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Circulating MiR-125b as a marker predicting chemoresistance in breast cancerThe potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancerTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer.Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trialEvaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patientsThe impact of expression profiling on prognostic and predictive testing in breast cancer.Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy.Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patientsCell killing and resistance in pre-operative breast cancer chemotherapyNeoadjuvant chemotherapy and pathologic response: a retrospective cohortNeo-adjuvant hormonal therapy.State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trialNeoadjuvant chemotherapy for early breast cancer.Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.Dual HER2-targeted approaches in HER2-positive breast cancer.Histopathologic changes following neoadjuvant chemotherapy in various malignancies.Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer.The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy.Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelFine-needle aspiration cytology of triple-negative basal-like breast cancer.Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
P2860
Q24812541-4563F196-5D23-40E7-806A-7748C561944DQ28066481-685FF735-390E-4C6B-A9BC-84878AF4CAA2Q28270514-F528698D-A6AD-461D-93F9-6C81B5D3BDABQ28482362-FAB3D259-FFFF-407E-96C7-CF02139B9101Q33480671-8AC15FB3-F8E1-4BF8-B9B3-43B8EE1F6B1EQ33813431-F4BE442F-4D9F-497C-A17E-7F10E32C2403Q34012047-FBD9DC83-40C3-431F-A1A2-F71BCB54F4C4Q34433737-D4D13362-F8BD-48B0-950A-7CDE3D230D08Q35141952-BB1F1B34-75AA-4AAF-9A56-AF2BA5EF407EQ35145309-F56C310E-6703-47F8-981A-93AF5D1BB241Q35450768-2EB887B4-ECDB-4C17-BAE7-2C5AE811C822Q35558914-CA0EB0A8-355B-4E15-AA52-A91B4B1662B6Q35588813-845AF6E8-F30E-4FC9-A142-9DFC39F4D312Q35663515-F1D6BC4C-C89C-4CCA-91E2-D105D66F7EF5Q35769768-7F54B6F6-4FB7-4CAB-81F5-1A552EFB6DA9Q35806203-BCE6B15D-CBF9-4F03-AFFD-2BD955BA13E9Q35889626-43117003-D11F-4E86-A171-528B3289972FQ36244131-938594D8-DB0B-46C4-AE6F-FBD31BA4812EQ36245392-F1B529BB-D966-4746-8AD3-EF6100111EDFQ36612439-909C0CB2-6513-4E86-A776-3F08B27185EFQ36763988-28F1C7C4-DD03-49E4-9957-B2F156FA7982Q36812607-E93312F2-07EC-45D2-8450-B1810A0073B0Q36935858-1E08F06F-F67C-4C55-AAEE-A9367A6D1ECEQ37121880-B83AAFF4-1664-42D4-8EBE-61567FA329A8Q37244111-C4F5293D-C309-4D1A-B78C-5F884B6D72D8Q37347500-9B4F3B0D-292F-4DD7-A588-81FBAC7BD322Q37510892-FC9BEF1D-8C73-4A82-87AF-97A966510569Q37835106-AE0A6A0C-DF04-441F-B3E4-FDBD86968CFAQ37940203-1D13AD7D-6989-4DD5-9F50-944070CDC2BFQ38115304-1E4A4CA7-0353-41D2-92B9-0820E471AF53Q38397572-10E86B3C-A7B2-4CD2-89BB-D7339552DA17Q38427892-4DFB2FB8-6527-48D5-A48E-3BA6AD206DFEQ38696564-72AB3C03-0038-46A3-B968-81A0865F67A7Q39279806-848C656E-81A9-40E6-A90D-FBF226CACE2BQ40195184-BD9ADEAA-E133-4386-BF1E-C355E1A30E90Q40382522-798CBACB-FBCB-44DD-B751-5D816ABABAD6Q41140406-F71D564B-B05B-4A9D-8150-3B2A9CFA7EC3Q42495758-D601EDD4-13AE-4B98-BCEF-3835EACFA1D8Q42504088-B73E0170-9409-4057-ABE5-828067CA6F37Q43430523-6D34F02C-1D5C-430C-AF11-4D32CCB81E15
P2860
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Breast cancer response to neoa ...... ers and relation with outcome.
@en
Breast cancer response to neoa ...... ers and relation with outcome.
@nl
type
label
Breast cancer response to neoa ...... ers and relation with outcome.
@en
Breast cancer response to neoa ...... ers and relation with outcome.
@nl
prefLabel
Breast cancer response to neoa ...... ers and relation with outcome.
@en
Breast cancer response to neoa ...... ers and relation with outcome.
@nl
P2093
P2860
P356
P1476
Breast cancer response to neoa ...... ers and relation with outcome.
@en
P2093
Faneyte IF
Peterse JL
Remijnse PL
Rodenhuis S
Schrama JG
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600749
P407
P577
2003-02-01T00:00:00Z